US Phase 2 Trial of Anavex 2-73 Surpasses Initial Enrollment Goal

Print Friendly, PDF & Email

INTERESTING CASE STUDY A TRIAL DRUG THAT INFLUENCES MITOCHONDRIA: U.S. enrollment for a Phase 2 clinical trial of investigational therapy Anavex 2-73 (blarcamesine) for Rett syndrome has surpassed its initial target number of participants by nearly 50%. Anavex Life Sciences announced in a press release that it expects to report top-line results later this year. The study, known […]